SECURITIES AND EXCHANGE COMMISSION

                             Washington, D.C. 20549


                                   FORM 8-A/A

                           AMENDING FORM 8-A FILED ON
                                  JULY 18, 2000




                FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES
                     PURSUANT TO SECTION 12(b) OR (g) OF THE
                         SECURITIES EXCHANGE ACT OF 1934


                          Miravant Medical Technologies
             (Exact name of Registrant as specified in its charter)

         Delaware                                       77-0222872
(State of incorporation or organization)              (IRS Employer I.D. No.)

                    336 Bollay Drive, Santa Barbara, CA 93117
                    (Address of principal executive offices)

If this form relates to the  registration  of a class of securities  pursuant to
Section  12(b)  of  the  Exchange  Act  and is  effective  pursuant  to  General
Instruction A.(c), check the following box.

If this form relates to the  registration  of a class of securities  pursuant to
Section  12(g)  of  the  Exchange  Act  and is  effective  pursuant  to  General
Instruction A.(d), check the following box. |X|

Securities Act registration statement file number to which this form relates (if
applicable): Not applicable.

Securities to be registered pursuant to Section 12(b) of the Act:


                                      None


                                (Title of Class)


    Securities to be registered pursuant to Section 12(g) of the Act: NASDAQ


                         Preferred Stock Purchase Rights

This Form 8-A/A amends and  supplements  the Form 8-A filed by Miravant  Medical
Technologies  (the  "Company")  on July 18, 2000 (the "Form  8-A").  Capitalized
terms used  without  definition  herein  shall have the meaning set forth in the
Form 8-A.



Item 1.           Description of Registrant's Securities to be Registered

         Item 1 of the Form 8-A is amended and supplemented by adding the
following:

     On April 24,  2001,  the Board of Directors  of the Company  authorized  an
amendment to the  Preferred  Stock Rights  Agreement,  dated as of July 13, 2000
(the  "Rights   Agreement"),   between  the  Company  and  U.S.  Stock  Transfer
Corporation, as Rights Agent. The amendment revised the definition of "Acquiring
Person" in the Rights Agreement as it relates to Pharmacia Corporation.

         The amendment is attached as Exhibit 4.2 hereto and incorporated herein
by reference.


Item 2.           Exhibits

                    4.1  Preferred Stock Rights Agreement,  dated as of July 13,
                         2000,  between Miravant  Medical  Technologies and U.S.
                         Stock Transfer Corporation including the Certificate of
                         Designation,  the form of  Rights  Certificate  and the
                         Summary of Rights  attached  thereto as  Exhibits A, B,
                         and C,  respectively.  (incorporated  by  reference  to
                         Exhibit 4.1 to the Company's  Report on Form 8-A, filed
                         July 18, 2000)

                    4.2  Amendment  to the Rights  Agreement,  dated as of April
                         24, 2001,  between  Miravant  Medical  Technologies and
                         U.S. Stock Transfer Corporation,  as Rights Agent (also
                         incorporated   by  reference  to  Exhibit  4.1  to  the
                         Company's  Current  Report on Form  8-K,  filed May 24,
                         2001)






                                 SIGNATURE

         Pursuant to the requirements of Section 12 of the Securities Exchange
Act of 1934, the Registrant has duly caused this registration statement to be
signed on its behalf by the undersigned, thereunto duly authorized.


                          Miravant Medical Technologies


 Dated: May 24, 2001                              By:   /s/ John M. Philpott
                                                         --------------------
                                                            John M. Philpott
                                                        Chief Financial Officer